Simcere's Montmorillonite (Biqi) passed Quality Consistency Evaluation for Generic Drugs

According to the database of the State Food and Drug Administration, "Biqi®-Montmorillonite Powder" manufactured by Simcere Pharmaceutical (Hainan) Co., Ltd. is among the first batch of montmorillonite powder products to have passed the SFDA's Quality Consistency Evaluation for Generic Drugs.

Biqi® is a Class I OTC drug for diarrhea. Biqi® APIs and preparations have passed the EU GMP certification, and are also included in the national health insurance catalogue since 2004


Related News